These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

809 related articles for article (PubMed ID: 23261049)

  • 21. Evaluation of chimeric DNA vaccines consisting of premembrane and envelope genes of Japanese encephalitis and dengue viruses as a strategy for reducing induction of dengue virus infection-enhancing antibody response.
    Sjatha F; Kuwahara M; Sudiro TM; Kameoka M; Konishi E
    Microbiol Immunol; 2014 Feb; 58(2):126-34. PubMed ID: 24372832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dendritic Cell Targeting Using a DNA Vaccine Induces Specific Antibodies and CD4
    Zaneti AB; Yamamoto MM; Sulczewski FB; Almeida BDS; Souza HFS; Ferreira NS; Maeda DLNF; Sales NS; Rosa DS; Ferreira LCS; Boscardin SB
    Front Immunol; 2019; 10():59. PubMed ID: 30761131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-level expression of recombinant dengue virus type 2 envelope domain III protein and induction of neutralizing antibodies in BALB/C mice.
    Zhang ZS; Yan YS; Weng YW; Huang HL; Li SQ; He S; Zhang JM
    J Virol Methods; 2007 Aug; 143(2):125-31. PubMed ID: 17532481
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression and purification of an immunogenic dengue virus epitope using a synthetic consensus sequence of envelope domain III and Saccharomyces cerevisiae.
    Nguyen NL; Kim JM; Park JA; Park SM; Jang YS; Yang MS; Kim DH
    Protein Expr Purif; 2013 Apr; 88(2):235-42. PubMed ID: 23376461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies.
    Vietheer PT; Boo I; Drummer HE; Netter HJ
    Antivir Ther; 2007; 12(4):477-87. PubMed ID: 17668556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression and purification of Dengue virus type 2 envelope protein as a fusion with hepatitis B surface antigen in Pichia pastoris.
    Bisht H; Chugh DA; Swaminathan S; Khanna N
    Protein Expr Purif; 2001 Oct; 23(1):84-96. PubMed ID: 11570849
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dengue virus envelope domain III immunization elicits predominantly cross-reactive, poorly neutralizing antibodies localized to the AB loop: implications for dengue vaccine design.
    Li XQ; Qiu LW; Chen Y; Wen K; Cai JP; Chen J; Pan YX; Li J; Hu DM; Huang YF; Liu LD; Ding XX; Guo YH; Che XY
    J Gen Virol; 2013 Oct; 94(Pt 10):2191-2201. PubMed ID: 23851440
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope.
    Metz SW; Thomas A; White L; Stoops M; Corten M; Hannemann H; de Silva AM
    Virol J; 2018 Apr; 15(1):60. PubMed ID: 29609659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serotype specificity of recombinant fusion protein containing domain III and capsid protein of dengue virus 2.
    Izquierdo A; Valdés I; Gil L; Hermida L; Gutiérrez S; García A; Bernardo L; Pavón A; Guillén G; Guzmán MG
    Antiviral Res; 2012 Jul; 95(1):1-8. PubMed ID: 22554934
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Production and immunogenicity of chimeric virus-like particles containing porcine reproductive and respiratory syndrome virus GP5 protein.
    Wang W; Chen X; Xue C; Du Y; Lv L; Liu Q; Li X; Ma Y; Shen H; Cao Y
    Vaccine; 2012 Nov; 30(49):7072-7. PubMed ID: 23036496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dengue-2 virus-like particle (VLP) based vaccine elicits the highest titers of neutralizing antibodies when produced at reduced temperature.
    Boigard H; Cimica V; Galarza JM
    Vaccine; 2018 Nov; 36(50):7728-7736. PubMed ID: 30377067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant vesicular stomatitis virus-based dengue-2 vaccine candidate induces humoral response and protects mice against lethal infection.
    Lauretti F; Chattopadhyay A; de Oliveira França RF; Castro-Jorge L; Rose J; Fonseca BA
    Hum Vaccin Immunother; 2016 Sep; 12(9):2327-33. PubMed ID: 27185081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A DNA vaccine candidate expressing dengue-3 virus prM and E proteins elicits neutralizing antibodies and protects mice against lethal challenge.
    De Paula SO; Lima DM; de Oliveira França RF; Gomes-Ruiz AC; da Fonseca BA
    Arch Virol; 2008; 153(12):2215-23. PubMed ID: 19002647
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant Dengue Virus 4 Envelope Glycoprotein Virus-Like Particles Derived from Pichia pastoris are Capable of Eliciting Homotypic Domain III-Directed Neutralizing Antibodies.
    Khetarpal N; Shukla R; Rajpoot RK; Poddar A; Pal M; Swaminathan S; Arora U; Khanna N
    Am J Trop Med Hyg; 2017 Jan; 96(1):126-134. PubMed ID: 27821688
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant retrovirus-derived virus-like particle-based vaccines induce hepatitis C virus-specific cellular and neutralizing immune responses in mice.
    Huret C; Desjardins D; Miyalou M; Levacher B; Amadoudji Zin M; Bonduelle O; Combadière B; Dalba C; Klatzmann D; Bellier B
    Vaccine; 2013 Mar; 31(11):1540-7. PubMed ID: 22634300
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine.
    Galula JU; Shen WF; Chuang ST; Chang GJ; Chao DY
    J Virol; 2014 Sep; 88(18):10813-30. PubMed ID: 25008922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A consensus envelope protein domain III can induce neutralizing antibody responses against serotype 2 of dengue virus in non-human primates.
    Chen HW; Liu SJ; Li YS; Liu HH; Tsai JP; Chiang CY; Chen MY; Hwang CS; Huang CC; Hu HM; Chung HH; Wu SH; Chong P; Leng CH; Pan CH
    Arch Virol; 2013 Jul; 158(7):1523-31. PubMed ID: 23456422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dimerization of Dengue Virus E Subunits Impacts Antibody Function and Domain Focus.
    Thomas A; Thiono DJ; Kudlacek ST; Forsberg J; Premkumar L; Tian S; Kuhlman B; de Silva AM; Metz SW
    J Virol; 2020 Aug; 94(18):. PubMed ID: 32611757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Dengue Virus Serotype 1 mRNA-LNP Vaccine Elicits Protective Immune Responses.
    Wollner CJ; Richner M; Hassert MA; Pinto AK; Brien JD; Richner JM
    J Virol; 2021 May; 95(12):. PubMed ID: 33762420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice.
    Block OK; Rodrigo WW; Quinn M; Jin X; Rose RC; Schlesinger JJ
    Vaccine; 2010 Nov; 28(51):8085-94. PubMed ID: 20959154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.